1504024-80-9

Upstream product

• 526-75-0 2,3-Dimethylphenol 
• 108-12-3 isopentanoyl chloride 
• 503-74-2 3-methylbutyric acid 

Downstream Products

• 1609476-83-6 3-(4-(2,3-dimethyl-4-(3-methylbutanoyl)phenoxy)butoxy)benzoic acid 
• 1609477-37-3 C₂₅H₃₂O₅ 
• 1609476-87-0 2-(4-(2,3-dimethyl-4-(3-methylbutanoyl)phenoxy)butoxy)benzoic acid 
• 1609477-41-9 C₂₅H₃₂O₅ 
• 1609476-91-6 3-chloro-4-(4-(2,3-dimethyl-4-(3-methylbutanoyl)phenoxy)butoxy)benzoic acid 
• 1609477-45-3 C₂₅H₃₁ClO₅ 
• 1609476-95-0 5-(4-(2,3-dimethyl-4-(3-methylbutanoyl)phenoxy)butoxy)-2-fluorobenzoic acid 
• 1609477-49-7 C₂₅H₃₁FO₅ 
• 1609476-75-6 methyl 4-(4-(2,3-dimethyl-4-(3-methylbutanoyl)phenoxy)butoxy)benzoate 
• 1609476-79-0 4-(4-(2,3-dimethyl-4-(3-methylbutanoyl)phenoxy)butoxy)benzoic acid 

Relevant academic research and scientific papers

METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF

Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators (PAMS), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): Pharmacological characterization and assessment in a rat model of cocaine dependence

As part of our ongoing small-molecule metabotropic glutamate (mGlu) receptor positive allosteric modulator (PAM) research, we performed structure-activity relationship (SAR) studies around a series of group II mGlu PAMs. Initial analogues exhibited weak activity as mGlu2 receptor PAMs and no activity at mGlu3. Compound optimization led to the identification of potent mGlu2/3 selective PAMs with no in vitro activity at mGlu1,4-8 or 45 other CNS receptors. In vitro pharmacological characterization of representative compound 44 indicated agonist-PAM activity toward mGlu2 and PAM activity at mGlu 3. The most potent mGlu2/3 PAMs were characterized in assays predictive of ADME/T and pharmacokinetic (PK) properties, allowing the discovery of systemically active mGlu2/3 PAMs. On the basis of its overall profile, compound 74 was selected for behavioral studies and was shown to dose-dependently decrease cocaine self-administration in rats after intraperitoneal administration. These mGlu2/3 receptor PAMs have significant potential as small molecule tools for investigating group II mGlu pharmacology.